Reps will tout new evidence that Fosamax increases bone density better than Actonel

Reps will tout new evidence that Fosamax increases bone density better than Actonel in postmenopausal women.

But this is only part of the story.

It's true that a new study suggests Fosamax (alendronate) increases bone density of the hip by 3.4% in one year. This is compared to only 2.1% for Actonel (risedronate).

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote